# NantCapital

> NantCapital is a VC fund backing Therapeutics and Health Diagnostics. See 8 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: VC Fund
- Location: Culver City, United States
- Total investments: 8
- Last investment: Mar 2023
- Lead investor: 63%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/company/nantworks
- X (Twitter): https://twitter.com/nantcapital
- Website: https://nantworks.com

NantCapital is a VC fund in Culver City focused on Therapeutics and Health Diagnostics. They are fast entering a new age. A worldwide shift as significant as any in history. They call it The Cognitive Age. Combining the collective promise of science, technology and communication. And then making it accessible to all people.

## Contacts

5 contacts available for NantCapital. Shizune tracks 2 team members at NantCapital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nantcapital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 38% |
| Health Diagnostics | 3 | 38% |
| Medical | 2 | 25% |
| Health Care | 2 | 25% |
| Solar | 1 | 13% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Debt | 2 | 25% |
| Post-IPO Equity | 2 | 25% |
| Series A | 1 | 13% |
| Series B | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Patrick Soon-Shiong | Founder | 4 | https://shizune.co/investors/profile/patrick-soon-shiong-f565 |
| Richard Binier | CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NantHealth | NantHealth is a healthcare company providing an evidence-based platform for healthcare diagnostics. It is a transformational healthcare company converging science and technology through an integrated clinical platform that’s empowering physicians, patients, payers, and researchers to transcend the traditional barriers of today’s healthcare system.The company's solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical delivery with clinical data and promoting wellness for a healthier, happier world. They are building an integrated, evidence-based, genomically-informed, personalized approach to the delivery of care and the development of next-generation healthcare solutions. | $22.5M | Post-IPO Debt | Mar 06, 2023 |  |
| ImmunityBio | NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. | $50M | Post-IPO Debt | Dec 12, 2022 |  |
| ImmunityBio | NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. | $107M | Post-IPO Equity | Dec 12, 2022 |  |
| Heliogen | Heliogen is a renewable energy technology company focused on eliminating the need for fossil fuels in heavy industry and powering a sustainable future. The company’s AI-enabled, modular concentrated solar technology aims to cost-effectively deliver near 24/7 carbon-free energy in the form of heat, power, or green hydrogen fuel at scale – forthe first time in history. Heliogen was created at Idealab, the leading technology incubator founded by Bill Gross in 1996. For more information about Heliogen, please visit heliogen.com. | $25M | Series A | Apr 08, 2020 |  |
| Heliogen | Heliogen is a renewable energy technology company focused on eliminating the need for fossil fuels in heavy industry and powering a sustainable future. The company’s AI-enabled, modular concentrated solar technology aims to cost-effectively deliver near 24/7 carbon-free energy in the form of heat, power, or green hydrogen fuel at scale – forthe first time in history. Heliogen was created at Idealab, the leading technology incubator founded by Bill Gross in 1996. For more information about Heliogen, please visit heliogen.com. | $10M | Series A | Oct 09, 2018 |  |
| PacketFabric | PacketFabric develops a next-generation networking platform to redefine network connectivity. It is a private layer 2 network as a service, providing scalable and secure connectivity between colocation facilities, to major cloud providers, and Internet Exchanges. PacketFabric is cost-effective and scalable network connectivity and all of itsservices are provided via the company's portal and API.PacketFabric was founded on 2015 and is headquartered in Culver City, California. | $25M | Series B | Jan 19, 2018 |  |
| Benitec Biopharma | Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases.Their transformational technology, ddRNAi, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. Compared to traditional approaches to RNAintereference, ddRNAi is easier to deliver, safer to us, more targeted and more efficient.Benitec has a pipeline of in-house and partnered drug development programs based on ddRNAI, including Hepatitis C and B, cancer-associated pain and drug-resistant lung cancer. Our Hepatitis C program is nearing clinical trials in 2013.ddRNAi has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. The technology is available from Benitec under a variety of licence options. | $4.1M | Post-IPO Equity | Mar 13, 2017 |  |
| ImmunityBio | NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. |  | Post-IPO Equity |  |  |

8 of 8 investments shown.

## Co-investors
- [Neotribe Ventures](https://shizune.co/investors/profile/neotribe-ventures) — VC Fund, 2 deals together
- Highbridge Capital Management — VC Fund, 1 deal together
- [MUUS](https://shizune.co/investors/profile/muus-523a) — VC Fund, 1 deal together
- [Prime Movers Lab](https://shizune.co/investors/profile/prime-movers-lab) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does NantCapital invest in?

NantCapital invests primarily in Therapeutics, Health Diagnostics and Medical startups, most often at Post-IPO Debt and Post-IPO Equity stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact NantCapital?

Public channels for NantCapital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NantCapital?

The team at NantCapital includes Patrick Soon-Shiong (Founder) and Richard Binier (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co